Luca Valenti

48.3k total citations · 10 hit papers
367 papers, 16.8k citations indexed

About

Luca Valenti is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Luca Valenti has authored 367 papers receiving a total of 16.8k indexed citations (citations by other indexed papers that have themselves been cited), including 269 papers in Epidemiology, 91 papers in Hepatology and 79 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Luca Valenti's work include Liver Disease Diagnosis and Treatment (252 papers), Diet, Metabolism, and Disease (71 papers) and Iron Metabolism and Disorders (53 papers). Luca Valenti is often cited by papers focused on Liver Disease Diagnosis and Treatment (252 papers), Diet, Metabolism, and Disease (71 papers) and Iron Metabolism and Disorders (53 papers). Luca Valenti collaborates with scholars based in Italy, United States and Sweden. Luca Valenti's co-authors include Paola Dongiovanni, Silvia Fargion, Anna Ludovica Fracanzani, Stefano Romeo, Raffaela Rametta, Elisabetta Bugianesi, Valério Nobili, Mohammed Eslam, Marco Maggioni and Domenico Accili and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Luca Valenti

355 papers receiving 16.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetics and epigenetics of NAFLD and NASH: Clinical impact

2017 692 citations Luca Valenti, Stefano Romeo et al. Journal of Hepatology profile →
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

2024 585 citations Frank Tacke, Vincent Wai‐Sun Wong et al. Journal of Hepatology profile →
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

2008 530 citations Anna Ludovica Fracanzani, Luca Valenti et al. Hepatology profile →
Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease†

2010 497 citations Luca Valenti, Ann K. Daly et al. Hepatology profile →
Update on NAFLD genetics: From new variants to the clinic

2020 261 citations Luca Valenti et al. Journal of Hepatology profile →
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease

2023 99 citations Gong Feng, Luca Valenti et al. Nature Reviews Gastroenterology & Hepatology profile →
The first MASH drug therapy on the horizon: Current perspectives of resmetirom

2024 82 citations Salvatore Petta, Giovanni Targher et al. Liver International profile →
Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease

2024 56 citations Alessandro Cherubini, Serena Pelusi et al. profile →
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary

2024 47 citations Frank Tacke, Vincent Wai‐Sun Wong et al. profile →
Metabolic Dysfunction–Associated Steatotic Liver Disease

2025 19 citations Giovanni Targher, Luca Valenti et al. profile →

Peers

Countries citing papers authored by Luca Valenti

Since Specialization

Citations

This map shows the geographic impact of Luca Valenti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Valenti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Valenti more than expected).

Fields of papers citing papers by Luca Valenti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Valenti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Valenti. The network helps show where Luca Valenti may publish in the future.

Co-authorship network of co-authors of Luca Valenti

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Valenti. A scholar is included among the top collaborators of Luca Valenti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Valenti. Luca Valenti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SLC7A11 transporter maintains critical nonessential amino acids levels to hamper ferroptosis during MASLD progression 2025 ·Science Bulletin ·(unknown), Luca Valenti	1
2	The first MASH drug therapy on the horizon: Current perspectives of resmetirom breakdown → 2024 ·Liver International ·Salvatore Petta, Giovanni Targher, Stefano Romeo, Utpal B. Pajvani, Ming‐Hua Zheng, Alessio Aghemo, Luca Valenti	82
3	Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease 2024 ·Nature Medicine ·Oveis Jamialahmadi, Antonio De Vincentis, Federica Tavaglione, Francesco Malvestiti, Ruifang Li‐Gao, Rosellina Margherita Mancina, Marcus Alvarez, (unknown), Samantha Maurotti, Umberto Vespasiani‐Gentilucci, Frits R. Rosendaal, Julia Kozlitina, Päivi Pajukanta, François Pattou, Luca Valenti, Stefano Romeo	34
4	Estrogen–ER‐α axis induces PNPLA3 p.I148M protein variant to promote steatotic liver disease susceptibility in women 2024 ·Clinical and Translational Medicine ·Alessandro Cherubini, (unknown), Serena Pelusi, Luca Valenti	3
5	Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models 2024 ·Journal of Hepatology ·(unknown), María Manuela Martins, (unknown), (unknown), (unknown), (unknown), Kessarin Thanapirom, Walid Al‐Akkad, (unknown), Guido Baselli, Andrew Hall, Tu Vinh Luong, Jan‐Willem Taanman, Michèle Vacca, Luca Valenti, Stefano Romeo, Giuseppe Mazza, Massimo Pinzani, Krista Rombouts	19
6	Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals 2023 ·Liver International ·Serena Pelusi, Cristiana Bianco, Massimo Colombo, Giuliana Cologni, P. Del Poggio, Nicola Pugliese, Daniele Prati, Marie Graciella Pigozzi, Roberta D’Ambrosio, Pietro Lampertico, S. Fagiuoli, Luca Valenti, (unknown)	7
7	Nailfold Videocapillaroscopic Alterations as Markers of Microangiopathy in COVID-19 Patients 2023 ·Journal of Clinical Medicine ·Roberta Gualtierotti, Sharon Fox, (unknown), (unknown), Luca Valenti, María Orietta Borghi, Pier Luigi Meroni, Massimo Cugno, Flora Peyvandi, (unknown)	3
8	SARS-CoV-2 infection in children: A 24 months experience with focus on risk factors in a pediatric tertiary care hospital in Milan, Italy 2023 ·Frontiers in Pediatrics ·Giada Di Pietro, Luisa Ronzoni, (unknown), Claudia Tagliabue, (unknown), Raffaella Pinzani, Samantha Bosis, (unknown), Luca Valenti	4
9	Salivary proteomic profile of young healthy subjects 2023 ·Frontiers in Molecular Biosciences ·Paola Dongiovanni, Marica Meroni, Gilda Aiello, Alfonsina D’Amato, (unknown), Sara Casati, Giovanni Damiani, Chiara Fenoglio, Daniela Galimberti, Enzo Grossi, Daniele Prati, Giuseppe Lamorte, Cristiana Bianco, Luca Valenti, Alessio Soggiù, Stefano Zapperi, Caterina A. M. La Porta, Massimo Del Fabbro, Gianluca Martino Tartaglia	1
10	Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades 2023 ·Digestive and Liver Disease ·Rosa Lombardi, (unknown), (unknown), Annalisa Cespiati, E. Fatta, C. Bertelli, (unknown), Giuseppina Pisano, E.A. Pulixi, Paolo Francione, Gabriele Maffi, (unknown), Paola Dongiovanni, Marica Meroni, Larry Burdick, Daniela Bignamini, Marco Maggioni, Luca Valenti, Silvia Fargion, Anna Ludovica Fracanzani	2
11	Liver Involvement in Patients with Rare MBOAT7 Variants and Intellectual Disability: A Case Report and Literature Review 2023 ·Genes ·Luisa Ronzoni, (unknown), Francesco Malvestiti, (unknown), Cristiana Bianco, (unknown), Margherita Baldassarri, Francesca Ariani, (unknown), Serena Pelusi, Alessandra Renieri, Daniele Prati, Luca Valenti	2
12	Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease breakdown → 2023 ·Nature Reviews Gastroenterology & Hepatology ·Gong Feng, Luca Valenti, Vincent Wai‐Sun Wong, Yasser Fouad, Yusuf Yılmaz, Won Kim, Giada Sebastiani, Zobair M. Younossi, Virginia Hernández–Gea, Ming‐Hua Zheng	99
13	Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity 2022 ·Internal and Emergency Medicine ·Rosa Lombardi, Vincenzo La Mura, (unknown), (unknown), (unknown), (unknown), Marco Proietti, Irene Motta, (unknown), Elisa Maria Fiorelli, Matteo Cesari, Alessandra Bandera, Luca Valenti, Flora Peyvandi, Nicola Montano, Marina Baldini, Anna Ludovica Fracanzani	7
14	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach 2021 ·Alimentary Pharmacology & Therapeutics ·Jeffrey V. Lazarus, Henry E. Mark, Massimo Colombo, Sandro Demaio, John Dillon, Jacob George, Hannes Hagström, Samantha Hocking, (unknown), Mark Nieuwenhuijsen, Mary E. Rinella, Manuel Romero‐Gómez, Joan B. Soriano, Jörn M. Schattenberg, Frank Tacke, Emmanuel Tsochatzis, Luca Valenti, Shira Zelber‐Sagi, M. Ashworth Dirac, Terry T.‐K. Huang	8
15	Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis 2021 ·Science Translational Medicine ·Junjie Yu, Changyu Zhu, Xiaobo Wang, KyeongJin Kim, Alberto Bartolomé, Paola Dongiovanni, Katherine P. Yates, Luca Valenti, Michele Carrer, Thorsten Sadowski, Li Qiang, Ira Tabas, Joel E. Lavine, Utpal B. Pajvani	94
16	Is there an ‘ideal’ diet for patients with NAFLD? 2021 ·European Journal of Clinical Investigation ·Nicola Pugliese, Maria Corina Plaz Torres, Salvatore Petta, Luca Valenti, Edoardo G. Giannini, Alessio Aghemo	45
17	A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? 2021 ·Cancers ·(unknown), Rebecca Darlay, Ruchi Shukla, Misti McCain, (unknown), (unknown), (unknown), Moustafa Fathy, Michael Atef Fawzy, Marco Y. W. Zaki, Ann K. Daly, (unknown), Alastair D. Burt, Beate Haugk, Heather J. Cordell, Cristiana Bianco, Jean‐François Dufour, Luca Valenti, Quentin M. Anstee, Helen L. Reeves	27
18	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9 2020 ·American Journal Of Pathology ·Chiara Macchi, Maria Francesca Greco, Margherita Botta, Paola Sperandeo, Paola Dongiovanni, Luca Valenti, Arrigo F.G. Cicero, Claudio Borghi, Maria Giovanna Lupo, Stefano Romeo, Alberto Corsini, Paolo Magni, Nicola Ferri, Massimiliano Ruscica	29
19	Interleukin 28B Polymorphism Predicts Pegylated Interferon Plus Ribavirin Treatment Outcome in Chronic Hepatitis C Genotype 4 2011 ·Hepatology ·Stella De Nicola, Alessio Aghemo, Maria Grazia Rumi, E. Galmozzi, Luca Valenti, R. Soffredini, Raffaele De Francesco, Gian Maria Prati, Roberta D’Ambrosio, Cristina Cheroni, Maria Francesca Donato, Massimo Colombo	67
20	Il potenziale polifenolico delle uve Nebbiolo: comparazione con le varieta internazionali ed italiane 2004 ·CINECA IRIS Institutional Research Information System (Fondazione Edmund Mach) ·Fulvio Mattivi, Luca Valenti	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact